Colon Cancer

Oral chemotherapy gets positive EU review for colon cancer after surgery

Published in Cancer Weekly, March 22nd, 2005

Roche announced that the European authorities have granted a positive opinion for Xeloda (capecitabine), an oral chemotherapy, to be used as an adjuvant treatment (post-surgery) for colon cancer. Full marketing approval for this new indication is anticipated within the next few months.

Adjuvant chemotherapy is one of the most common treatment approaches for colon cancer where chemotherapy is given in order to destroy any cancerous cells remaining in the body after the tumor has been surgically removed. Data from a major study (X-ACT)1 have shown that oral Xeloda is at least as effective and has a favorable toxicity profile to the intravenous chemotherapy commonly used...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-03-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry